Under the agreement, NovAliX is expected to use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the cystathionine-beta-synthase (CBS).
The Fondation Jerome Lejeune chief scientific officer Henri Blehaut said they look forward to progressing their research programs for treating trisomy 21 leveraging NovAliX expertise in structure-based drug design and capabilities in advanced lead generation methodologies.